Panitumumab in colon cancer: a review and summary of ongoing trials.

Abstract

Panitumumab is a fully human antibody developed against the human epidermal growth factor receptor receptor (EGFR/HER-1), which is overexpressed in > or = 75% of patients with colorectal cancer. As a fully human antibody, panitumumab can be administered without any premedication and has the promise of decreased infusion reactions. Clinical studies have… (More)

Topics

  • Presentations referencing similar topics